Survival Status and Predictors among ovarian Cancer Patients at Oncology Centers, Addis Ababa, Ethiopia, 2024
| dc.contributor.advisor | Jembere Tesfaye | |
| dc.contributor.author | Abrham Tesfaye | |
| dc.date.accessioned | 2025-08-12T19:34:43Z | |
| dc.date.available | 2025-08-12T19:34:43Z | |
| dc.date.issued | 2024-06-05 | |
| dc.description.abstract | Introduction: Ovarian cancer is the leading cause of death and has the worst prognosis among gynaecologic malignancies worldwide. In Ethiopia, ovarian cancer is the third most prevalent gynaecologic malignancy, following breast and cervical cancers. One of the key aspects of the strategic framework of the Ethiopian Federal Ministry of Health is to minimize the incidence and mortality of cancer as well as improve the quality of life of cancer patients. The survival rate of ovarian cancer has improved significantly with early detection and treatment. Despite extensive studies on the subject, studies on survival rate of ovarian cancer patients are still scarce. Objective: The main aim of this study was to assess the survival status and predictors among Ovarian Cancer Patients at Oncology Centers, Addis Ababa, Ethiopia, 2024. Method: A facility-based retrospective cohort study was conducted in oncology centers in Addis Ababa. All cases of ovarian cancer registered from January 1st, 2017 to December 31st, 2018 in Addis Ababa oncology centers were followed retrospectively for five-year survival (until December 31st, 2023). Descriptive statistics were used, and to determine the presence of differences in survival rate among predictors, Kaplan-Meier survival curve and log rank test were performed. The net effect of each predictor variable on time to death after ovarian cancer diagnosis was estimated using Cox regression at the 5% level of significance. Result: The study involved a total of 561 patients with ovarian cancer. Of these, 264 (47.1%) patients were died, yielding a crude mortality rate of 16.67 per 100(95%CI: 14.78–18.81) person-years. Overall, the median survival time was 43.4(95% CI, 40.39–47.37) months. The cumulative estimated 5-year survival rate following the diagnosis of ovarian cancer was 38.87% (95% CI, 34.05 to 43.68%). Independent predictors of mortality were advanced age (≥60) [AHR: 3.35, 95%CI: (1.23-9.18)], advanced FIGO stage (III&IV) [AHR: 2.29, 95%CI: (1.18-4.46)], and being a combined oral contraceptive user was protective [AHR: 0.45, 95%CI: (0.21-0.96)]. Conclusion and recommendation: Ovarian cancer patients had a lower overall survival rate when compared to those in high- and middle-income countries. Advanced FIGO stage, epithelial histology, advanced age, comorbidity, being a combined oral contraceptive user, chemo-surgery treatment mode, and treatment completion were significant predictors of mortality in ovarian cancer patients. As a result, early screening, early stage diagnosis, and early treatment should be emphasized since advanced stages are associated with high mortality. Keywords: Ovarian cancer patients, Predictors, Incidence, Time to death, survival status, Death. | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/6431 | |
| dc.language.iso | en_US | |
| dc.publisher | Addis Ababa University | |
| dc.subject | Ovarian cancer patients Predictors Incidence Time to death survival status Death | |
| dc.title | Survival Status and Predictors among ovarian Cancer Patients at Oncology Centers, Addis Ababa, Ethiopia, 2024 | |
| dc.type | Thesis |